Literature DB >> 8907697

Protective effect of L-propionylcarnitine on cyclosporine-induced nephrotoxicity.

A Bertelli1, L Giovannini, R Palla, M Migliori, V Panichi, B Andreini.   

Abstract

Nephrotoxicity has represented the major limitation in the use of cyclosporine A (CyA). The structural abnormalities at the level of the proximal tubular cells are necrosis, vacuolisation and lipid droplets, as well as CyA-induced glomerular afferent arteriole constriction and granular juxtaglomerular cell hyperplasia. The mode of action of vasoconstriction is not well known, but there appears to be substantial impairment of endothelial cell function leading to enhanced release of vasoconstrictors such as endothelin and thromboxane. L-propionylcarnitine (PC), one of the most potent analogues of carnitine, is able to correct and to prevent alterations in endothelial membrane permeability and it has been identified in the kidney of various animal species. To investigate a possible reduction of CyA-induced nephrotoxocity, we examined the effects of a pretreatment with PC before administering several doses of CyA in an isolated and perfused rat kidney. The histological findings showed that the perfusion with PC reduces the vasoconstrictive effect of CyA on the glomerular capillaries and preserves the tubular epithelium. The ratio of the diameter between the glomerular capillary tuft and Bowman's capsule was higher, while at the tubular level the ratio internal-diameter/diameter evaluated at the level of the basal membrane was lower in PC + CyA perfused kidneys than in only CyA perfused ones. The final value of perfusion pressure was lower in PC + CyA perfused kidneys than in only CyA perfused ones, confirming the histological findings. The release induced by CyA of alanine aminopeptidase (AAP) and N-acetyl-glucosaminidase (NAG), markers of tubular damage, was significantly reduced by pretreatment with PC. These data suggest that the pretreatment with PC reduces the CyA-induced nephrotoxicity in an isolated and perfused rat kidney.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8907697

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  4 in total

1.  Role of carnitine in disease.

Authors:  Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark Dp Willcox; Qian Garrett
Journal:  Nutr Metab (Lond)       Date:  2010-04-16       Impact factor: 4.169

2.  Protective effects of 2-deoxy-D-glucose on nephrotoxicity induced by cyclosporine A in rats.

Authors:  Zizhang Ouyang; Weiwei Cao; Shaohua Zhu; Xiaoping Liu; Zhihua Zhong; Xiangmao Lai; Huirong Deng; Sheng Jiang; Yan Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

3.  Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype.

Authors:  Zaher Armaly; Amir Abd El Qader; Adel Jabbour; Kamal Hassan; Rawi Ramadan; Abdalla Bowirrat; Bishara Bisharat
Journal:  BMC Nephrol       Date:  2015-08-13       Impact factor: 2.388

4.  Impact of pretreatment with carnitine and tadalafil on contrast-induced nephropathy in CKD patients.

Authors:  Zaher Armaly; Suheil Artol; Adel R Jabbour; Amer Saffouri; Nayef Habashi; Amir Abd Elkadir; Naser Ghattas; Raymond Farah; Safa Kinaneh; William Nseir
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.